Board of Pharmacy; regulation of crystalline polymorph psilocybin. Directs the Board of Pharmacy to promulgate regulations that allow for prescribing, dispensing, possessing, and using the pharmaceutical composition of crystalline polymorph psilocybin upon approval by the U.S. Food and Drug Administration and following rescheduling by the U.S. Drug Enforcement Administration.